SGS launches GMP-compliant NMR testing for Chinese pharma industry

SGS, world’s leading Testing, Inspection and Certification company, has expanded its analytical capabilities in China with the introduction of JEOL 400 MHz nuclear magnetic resonance (NMR) testing, delivering powerful structural analysis and high quantitative accuracy to good manufacturing practice (GMP)-compliant pharmaceutical testing and quality control (QC).

From research and development to commercial production, NMR delivers high-resolution structural clarity and quantitative precision, ensuring every batch meets the highest standards of identity, purity and quality. This non-destructive analytical technique complements chromatographic and spectroscopic techniques across the entire drug lifecycle, enabling:

• Active pharmaceutical ingredient (API) structure confirmation – verify molecular identity and stereochemistry
• Impurity and degradation profiling – detect and characterize trace components down to 0.1% w/w
• Polymorphism analysis – differentiate crystal forms without sample destruction
• Quantitative NMR (qNMR) – deliver accurate, traceable purity and assay results, directly linked to SI units
• All analyses are conducted under fully GMP-validated procedures, supported by comprehensive installation qualification (IQ)/operational qualification (OQ)/performance qualification (PQ), as well as data integrity controls and structured personnel training programs, ensuring robust performance and regulatory confidence.

This new service offers cost-effective, high-throughput analytical capability, making it ideal for routine quality control, identity testing, purity assessment and quantitation of synthesised drug substances and drug products, as well as raw materials. This expansion reinforces our commitment to innovative, compliant and high-value analytical solutions, supporting pharmaceutical manufacturers in ensuring product safety, efficacy and regulatory compliance.